This editorial describes the science behind clinical trials testing elafibranor and seladelpar in the treatment of primary biliary cholangitis.
No takes yet. Share an insight, caveat, or question.
Bernd Schnabl (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: